- News |
-
- Featured
-
Canada’s privacy commissioner launches investigation over the use..
As the years pass by, technology also widens, and more and more are being discovered. From simple gadgets..
- Business |
-
- Featured
-
Be an informer to I-T dept; earn up..
Sharing "specific information" with the income tax department about any benami..
- Tech & Industry |
-
- Featured
-
Gravitational wave event likely signaled birth of black..
The merger of two neutron stars that generated gravitational waves detected last year may have led to the birth..
- Entertainment |
-
- Topics
- Malayalam Film
- Media
- Music
- Youth
-
- Featured
-
Shawn Mendes Released Highly Anticipated Self-Titled Album Today
Los Angeles, CA : Multi-Platinum singer/songwriter Shawn Mendes released his highly anticipated self-titled third album today, via Island Records. Get..
-
- New Products |
-
- Topics
- General
-
- Featured
-
ZOTAC Introduces Its GeForce GTX 960 series graphics..
Dubai- ZOTAC International, a leading innovator and manufacturer of graphic cards and mini-
-
- Education |
-
- Topics
- Campus News
-
- Featured
-
ITM University, Gurgaon Student Palash Chhabra Represents Varsity..
New Delhi: Palash Chhabra, a student of ITM University,..
-
- Health |
-
- Topics
- Medical News
-
- Featured
-
Maharshi Shushruta, The Great Grandfather of Surgery!
by Ayurvedacharya Dr.Hitesh Jani Dr.Hitesh Jani
-
- Tourism |
-
- Topics
- Travel
- Food&Beverages
- Hospitality
-
- Featured
-
“Keraliya Ayurveda is Credible and Authentic”
Irina Gurjeva Irina Gurjeva is not just another vacationer in..
-
- Sports |
- Editor's column |
- Magazine |
EffRx and Nycomed Announces First European Filing for Marketing Approval of Osteoporosis Drug Targeting Increased Convenience for Patients
Published on September 22, 2010
Lausanne, Switzerland — The Lausanne, Switzerland, based drug delivery company EffRx Pharmaceuticals SA 
(“EffRx”) and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
The licensing agreement for EX101 between Nycomed and EffRx was announced early 2009 and Nycomed recently amended its original licensing agreement with EffRx and holds now exclusive rights to develop, manufacture and commercialise the effervescent formulation of alendronate for the treatment of osteoporosis in all territories in the world except USA and Japan.
EX101 will complement Nycomed’s osteoporosis portfolio, which consists of Preotact® (full-length parathyroid hormone [PTH 1-84]) for treatment of osteoporosis in post-menopausal women at high risk of fractures, and the company’s broad Calcium D3 product range for the prevention and an adjunct of the condition.
“This is obviously a key step in getting EX101 to the market and shows Nycomed’s commitment to get EX101 into their osteoporosis portfolio of products as soon as possible,” stated Christer Rosén, CEO of EffRx.
